Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Scinai Immunotherapeutics Ltd's Business Segments
Scinai Immunotherapeutics Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of 2025 ((Dec 31 2025))
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Annual Results
Revenue by Product & Service Category -
- License7.6%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 0 | 7.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Scinai Immunotherapeutics Ltd
The company operates in two main business areas: therapeutic development and contract development and manufacturing organization (CDMO) services. The CDMO segment provides development and manufacturing services subject to regulatory and quality standards. The company seeks to expand its CDMO business while advancing its therapeutic pipeline, which includes early-stage product candidates based on its NanoAbs technology platform. These therapeutic candidates are in development and currently do not generate revenue. The company relies on third parties and collaborators for development, commercialization, and marketing of its product candidates and holds licenses from MPG and UMG for its NanoAbs programs. Operations are conducted through manufacturing facilities in Jerusalem and Yavne, Israel. The company faces risks including operating losses, the need for additional financing, market demand for CDMO services, competition, regulatory compliance, and geopolitical risks related to its Israeli operations. It has a history of operating losses and requires substantial additional capital to fund operations and development programs. Failure to obtain financing could result in delays, reductions, or cessation of activities. As of December 31, 2025, the company had $1.6 million in cash and cash equivalents and reported operating losses of $7.5 million for the year then ended.
Scinai Immunotherapeutics Ltd is a biotechnology company focused on developing novel immunotherapies for the treatment of various diseases, particularly cancer. The company’s innovative approach centers on harnessing the body’s own immune system to fight diseases, combining advanced scientific research with state-of-the-art technologies. Below is a detailed overview of the segments, products, and services offered by Scinai Immunotherapeutics Ltd.
Segments
1. Cancer Immunotherapy:
- Scinai is primarily focused on developing therapies that enhance the immune systems ability to recognize and destroy cancer cells. This segment may include various approaches, such as monoclonal antibodies, immune checkpoint inhibitors, and adoptive cell transfer devices that harness T-cell therapy.
2. Autoimmune and Inflammatory Diseases:
- In addition to cancer, Scinai explores immunotherapeutic applications for autoimmune diseases where the immune system erroneously attacks the body’s own cells. This might encompass products aimed at modulating immune responses to restore normal function.
3. Infectious Diseases:
- The company may also seek to develop immunotherapies targeting infectious diseases by boosting the immune response against pathogens. This involves researching vaccines and therapeutic modalities to enhance immunity.
Products
1. Therapeutics:
- Scinai develops a range of therapeutic products designed specifically to stimulate or enhance the immune response. Examples of these might include:
- Monoclonal Antibodies: Engineered antibodies that target specific antigens on cancer cells, facilitating more effective destruction.
- CAR-T Cell Therapies: Customized therapies that modify a patient’s T-cells to enhance anti-tumor activity.
- Tumor Vaccines: Vaccines designed to provoke an immune response against specific tumor antigens to prevent recurrence.
2. Immune Modulators:
- Products that aim to regulate the immune systems activity, potentially shifting the immune response toward a more favorable outcome in cancer or autoimmune diseases. These may include:
- Cytokines: Molecules that help modulate the immune response.
- Checkpoint Inhibitors: Products designed to block pathways that suppress immune responses against tumors.
3. Diagnostic Tools:
- Scinai may also develop diagnostic products to detect biomarkers indicative of immune responses or cancer progression. These tools are crucial for personalized immunotherapy, allowing tailored treatment plans for patients.
Services
1. Research and Development:
- Scinai invests significantly in R&D for innovative immunotherapy solutions. Their services might encompass:
- Preclinical Studies: Conducting laboratory and animal studies to assess the efficacy and safety of new therapeutic candidates before clinical trials.
- Clinical Trials Management: Coordinating and managing clinical trials to evaluate the safety and effectiveness of their products in humans.
2. Partnerships and Collaborations:
- The company may engage in strategic partnerships with other biotech firms, research institutions, and pharmaceutical companies to enhance their development capabilities. These collaborations often aim to pool resources for R&D or co-develop products.
3. Consultative Services:
- Scinai could also offer advisory services to industry stakeholders on immunotherapy development, regulatory pathways, and market access strategies. This would provide valuable insights into navigating the complexities of bringing a therapeutic product to market.
4. Educational Initiatives:
- Initiatives aimed at educating healthcare stakeholders about the latest advancements in immunotherapy, including workshops, seminars, and publications to disseminate knowledge within the medical community.
Scinai Immunotherapeutics Ltd is committed to advancing the frontier of immunotherapy through innovative products, comprehensive services, and dedicated research efforts, aiming to improve patient outcomes and contribute to the evolving landscape of medical treatments.
Segments
1. Cancer Immunotherapy:
- Scinai is primarily focused on developing therapies that enhance the immune systems ability to recognize and destroy cancer cells. This segment may include various approaches, such as monoclonal antibodies, immune checkpoint inhibitors, and adoptive cell transfer devices that harness T-cell therapy.
2. Autoimmune and Inflammatory Diseases:
- In addition to cancer, Scinai explores immunotherapeutic applications for autoimmune diseases where the immune system erroneously attacks the body’s own cells. This might encompass products aimed at modulating immune responses to restore normal function.
3. Infectious Diseases:
- The company may also seek to develop immunotherapies targeting infectious diseases by boosting the immune response against pathogens. This involves researching vaccines and therapeutic modalities to enhance immunity.
Products
1. Therapeutics:
- Scinai develops a range of therapeutic products designed specifically to stimulate or enhance the immune response. Examples of these might include:
- Monoclonal Antibodies: Engineered antibodies that target specific antigens on cancer cells, facilitating more effective destruction.
- CAR-T Cell Therapies: Customized therapies that modify a patient’s T-cells to enhance anti-tumor activity.
- Tumor Vaccines: Vaccines designed to provoke an immune response against specific tumor antigens to prevent recurrence.
2. Immune Modulators:
- Products that aim to regulate the immune systems activity, potentially shifting the immune response toward a more favorable outcome in cancer or autoimmune diseases. These may include:
- Cytokines: Molecules that help modulate the immune response.
- Checkpoint Inhibitors: Products designed to block pathways that suppress immune responses against tumors.
3. Diagnostic Tools:
- Scinai may also develop diagnostic products to detect biomarkers indicative of immune responses or cancer progression. These tools are crucial for personalized immunotherapy, allowing tailored treatment plans for patients.
Services
1. Research and Development:
- Scinai invests significantly in R&D for innovative immunotherapy solutions. Their services might encompass:
- Preclinical Studies: Conducting laboratory and animal studies to assess the efficacy and safety of new therapeutic candidates before clinical trials.
- Clinical Trials Management: Coordinating and managing clinical trials to evaluate the safety and effectiveness of their products in humans.
2. Partnerships and Collaborations:
- The company may engage in strategic partnerships with other biotech firms, research institutions, and pharmaceutical companies to enhance their development capabilities. These collaborations often aim to pool resources for R&D or co-develop products.
3. Consultative Services:
- Scinai could also offer advisory services to industry stakeholders on immunotherapy development, regulatory pathways, and market access strategies. This would provide valuable insights into navigating the complexities of bringing a therapeutic product to market.
4. Educational Initiatives:
- Initiatives aimed at educating healthcare stakeholders about the latest advancements in immunotherapy, including workshops, seminars, and publications to disseminate knowledge within the medical community.
Scinai Immunotherapeutics Ltd is committed to advancing the frontier of immunotherapy through innovative products, comprehensive services, and dedicated research efforts, aiming to improve patient outcomes and contribute to the evolving landscape of medical treatments.